S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
NASDAQ:TFFP

TFF Pharmaceuticals Stock Forecast, Price & News

$7.61
+0.44 (+6.14%)
(As of 12/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.29
$7.61
50-Day Range
$6.86
$8.24
52-Week Range
$6.39
$21.14
Volume
188,188 shs
Average Volume
242,834 shs
Market Capitalization
$193.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.08
30 days | 90 days | 365 days | Advanced Chart
Receive TFFP News and Ratings via Email

Sign-up to receive the latest news and ratings for TFF Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


TFF Pharmaceuticals logo

About TFF Pharmaceuticals

TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform in the United States and Australia. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which has completed Phase I clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in the Phase I clinical trials used for the prevention of lung transplant rejection. It is also developing other dry powder products, such as Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various types of pain; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.

Headlines

TFF Pharmaceuticals (NASDAQ:TFFP) Issues Earnings Results
November 16, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TFFP
Fax
N/A
Employees
4
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$1.88 per share

Profitability

Net Income
$-18.57 million
Pretax Margin
-35,375.00%

Debt

Price-To-Earnings

Miscellaneous

Free Float
22,860,000
Market Cap
$193.08 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
12/07/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/09/2022

MarketRank

Overall MarketRank

2.09 out of 5 stars

Medical Sector

530th out of 1,394 stocks

Pharmaceutical Preparations Industry

247th out of 673 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












TFF Pharmaceuticals (NASDAQ:TFFP) Frequently Asked Questions

Is TFF Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TFF Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TFF Pharmaceuticals stock.
View analyst ratings for TFF Pharmaceuticals
or view top-rated stocks.

How has TFF Pharmaceuticals' stock price been impacted by Coronavirus?

TFF Pharmaceuticals' stock was trading at $4.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TFFP stock has increased by 90.3% and is now trading at $7.61.
View which stocks have been most impacted by COVID-19
.

Are investors shorting TFF Pharmaceuticals?

TFF Pharmaceuticals saw a increase in short interest in the month of October. As of October 29th, there was short interest totaling 591,100 shares, an increase of 34.2% from the October 14th total of 440,400 shares. Based on an average daily trading volume, of 166,900 shares, the short-interest ratio is presently 3.5 days. Approximately 3.0% of the shares of the stock are short sold.
View TFF Pharmaceuticals' Short Interest
.

When is TFF Pharmaceuticals' next earnings date?

TFF Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, March 9th 2022.
View our earnings forecast for TFF Pharmaceuticals
.

How were TFF Pharmaceuticals' earnings last quarter?

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.15. The business had revenue of $0.05 million for the quarter, compared to analyst estimates of $1.70 million. During the same quarter in the prior year, the firm posted ($0.24) earnings per share.
View TFF Pharmaceuticals' earnings history
.

What price target have analysts set for TFFP?

4 brokerages have issued 12 month target prices for TFF Pharmaceuticals' stock. Their forecasts range from $14.00 to $37.00. On average, they expect TFF Pharmaceuticals' stock price to reach $25.50 in the next year. This suggests a possible upside of 235.1% from the stock's current price.
View analysts' price targets for TFF Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are TFF Pharmaceuticals' key executives?

TFF Pharmaceuticals' management team includes the following people:
  • Mr. Glenn R. Mattes, Pres, CEO & Director (Age 66, Pay $654.17k) (LinkedIn Profile)
  • Mr. Kirk Allen Coleman, CFO, Treasurer & Sec. (Age 49, Pay $361.67k)
  • Mr. Christopher Cano, COO & VP of Bus. Devel. (Age 50, Pay $343.12k)
  • Dr. James Brian Windsor, Chief Science Officer & Director (Age 55)

What other stocks do shareholders of TFF Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TFF Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), VBI Vaccines (VBIV), Akero Therapeutics (AKRO), VYNE Therapeutics (VYNE), Acer Therapeutics (ACER), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Chiasma (CHMA), Chimerix (CMRX) and DURECT (DRRX).

When did TFF Pharmaceuticals IPO?

(TFFP) raised $22 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 4,400,000 shares at a price of $5.00 per share. National Securities acted as the underwriter for the IPO.

What is TFF Pharmaceuticals' stock symbol?

TFF Pharmaceuticals trades on the NASDAQ under the ticker symbol "TFFP."

Who are TFF Pharmaceuticals' major shareholders?

TFF Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Gagnon Securities LLC (1.11%), BlackRock Inc. (1.02%), Carlson Capital L P (0.90%), Janney Montgomery Scott LLC (0.77%), GSA Capital Partners LLP (0.57%) and Geode Capital Management LLC (0.49%). Company insiders that own TFF Pharmaceuticals stock include Aaron GL Fletcher, Glenn R Mattes, James Brian Windsor, Kirk Allen Coleman, Lung Therapeutics, Inc, Malcolm Fairbairn, Randy H Thurman, Robert S Mills and Stephen Rocamboli.
View institutional ownership trends for TFF Pharmaceuticals
.

Which major investors are selling TFF Pharmaceuticals stock?

TFFP stock was sold by a variety of institutional investors in the last quarter, including Gagnon Securities LLC, Renaissance Technologies LLC, Apis Capital Advisors LLC, Millennium Management LLC, Two Sigma Investments LP, Morgan Stanley, Assenagon Asset Management S.A., and Two Sigma Advisers LP. Company insiders that have sold TFF Pharmaceuticals company stock in the last year include Glenn R Mattes, James Brian Windsor, Kirk Allen Coleman, Lung Therapeutics, Inc, Robert S Mills, and Stephen Rocamboli.
View insider buying and selling activity for TFF Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying TFF Pharmaceuticals stock?

TFFP stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG, GSA Capital Partners LLP, MYDA Advisors LLC, Janney Montgomery Scott LLC, Wolverine Trading LLC, National Asset Management Inc., Citadel Advisors LLC, and Raymond James & Associates. Company insiders that have bought TFF Pharmaceuticals stock in the last two years include Aaron GL Fletcher, Glenn R Mattes, Kirk Allen Coleman, and Malcolm Fairbairn.
View insider buying and selling activity for TFF Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of TFF Pharmaceuticals?

Shares of TFFP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TFF Pharmaceuticals' stock price today?

One share of TFFP stock can currently be purchased for approximately $7.61.

How much money does TFF Pharmaceuticals make?

TFF Pharmaceuticals has a market capitalization of $193.08 million. The company earns $-18.57 million in net income (profit) each year or ($1.11) on an earnings per share basis.

How many employees does TFF Pharmaceuticals have?

TFF Pharmaceuticals employs 4 workers across the globe.

What is TFF Pharmaceuticals' official website?

The official website for TFF Pharmaceuticals is www.tffpharma.com.

Where are TFF Pharmaceuticals' headquarters?

TFF Pharmaceuticals is headquartered at 2600 Via Fortuna Suite 360, Austin TX, 78746.

How can I contact TFF Pharmaceuticals?

TFF Pharmaceuticals' mailing address is 2600 Via Fortuna Suite 360, Austin TX, 78746. The company can be reached via phone at 737-802-1973 or via email at [email protected].


This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.